Deferred Tax Assets, Valuation Allowance of Verve Therapeutics, Inc. from 31 Dec 2020 to 31 Dec 2024

Taxonomy & unit: us-gaap: USD
Description: Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary: Verve Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2020 to 31 Dec 2024.
Verve Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2024 was $228,825,000, a 33% increase year-over-year.
Source SEC data: View on sec.gov

Deferred Tax Assets, Valuation Allowance, Quarterly (USD)

Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Verve Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q4 2024	$228,825,000	+$56,715,000	+33%	31 Dec 2024	10-K	27 Feb 2025	2024	FY
Q4 2023	$172,110,000	+$62,474,000	+57%	31 Dec 2023	10-K	27 Feb 2025	2024	FY
Q4 2022	$109,636,000	+$54,556,000	+99%	31 Dec 2022	10-K	27 Feb 2024	2023	FY
Q4 2021	$55,080,000	+$37,701,000	+217%	31 Dec 2021	10-K	02 Mar 2023	2022	FY
Q4 2020	$17,379,000			31 Dec 2020	10-K	14 Mar 2022	2021	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.